Data from the phase 3 METEOR trial presented at the 2016 annual meeting of the American Society of Clinical Oncology showed that cabozantinib reduced the risk of death in patients with advanced renal cell carcinoma by 34%, compared with everolimus.
Cabozantinib (Cabometyx) reduced the risk of death by 34% compared with everolimus (Afinitor) in patients with previously treated advanced renal cell carcinoma (RCC), according to updated data from the phase 3 METEOR trial presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO).1
The results, which were simultaneously published in The Lancet Oncology,2 showed a 4.9-month median overall survival (OS) benefit with cabozantinib. The risk of disease progression was reduced by 49% with the multi kinase inhibitor versus everolimus. Based on the METEOR trial’s results, the FDA approved cabozantinib in April 2016 for patients with advanced RCC who had prior antiangiogenic therapy.3
“In the phase 3 METEOR trial, treatment with cabozantinib was associated with a significant improvement in overall survival, as well as progression-free survival and objective response rate compared with everolimus in patients with advanced renal cell carcinoma. Cabozantinib is a new standard for patients with advanced RCC after prior antiangiogenic therapy,” lead author Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, said when presenting the data at ASCO.
The complete article can be accessed here: http://bit.ly/29Qpg9I.Jason M. Broderick is associate director, Digital Editorial, OncLive.com.
Neonatology Pricing and Network Participation Under State Balance Billing Regulations
October 2nd 2025This national study of neonatology services found no clear evidence that state surprise billing regulations influenced prices or provider network participation for the commercially insured.
Read More
Managed Care Reflections: A Q&A With Ge Bai, PhD, CPA
October 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The October issue features a conversation with Ge Bai, PhD, CPA, professor of accounting at Johns Hopkins Carey Business School and professor of health policy and management at Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.
Read More